

# **New Insights into the Pathophysiology of Type 1 and Type 2 Diabetes**

**April 30, 2025**

**New Insights into Metabolic and  
Cardiorenal Wellness in People with  
Diabetes: A Virtual CME Program for Africa**

**Giulio R. Romeo, MD  
Associate Chief, Adult Diabetes, Joslin Diabetes Center  
Staff Physician, Div. of Endocrinology, BIDMC  
Harvard Medical School**

Beth Israel Lahey Health   
Joslin Diabetes Center

# DISCLOSURES

---

- I have no financial relationships with any commercial entity producing healthcare-related products and/or services
- I have not received grants, compensation, or other support from pharmaceutical companies or drug-manufacturing entities.

## OBJECTIVES

---

- ❑ Review the interaction of genetic and environmental factors in the pathogenesis of type 1 and type 2 diabetes.
- ❑ Discuss key pathogenetic mechanisms for the development and progression of type 1 and type 2 diabetes.
- ❑ Outline the heterogeneity of diabetes presentations and associated risk of complications.

---

*“Chance favors only the prepared mind”* Louis Pasteur

COPYRIGHT


# Milestones in diabetes research and translation to treatment

## Nobel Prizes for Diabetes-related Research

Year	Category	Recipient	Contribution
1923	Medicine	F.G. Banting and J.J.R. Macleod	Discovery of insulin
1947	Medicine	C.F. Cori and G.T. Cori	Discovery of the course of the catalytic conversion of glycogen
1947	Medicine	B.A. Houssay	Discovery of the role of hormones released by the anterior pituitary lobe in the metabolism of sugar
1958	Chemistry	F. Sanger	Work on the structure of proteins, especially insulin
1971	Medicine	E.W. Sutherland	Discoveries concerning the mechanisms of action of hormones
1977	Medicine	R. Yalow	Development of radioimmunoassays for peptide hormones
1992	Medicine	E.H. Fischer and E.G. Krebs	Discoveries concerning reversible protein phosphorylation as a biologic regulatory mechanism

Polonski KS NEJM 2012; 367:1132-1340


*Such great variations in the amount of insulin required to reduce hyperglycemia are at times observed that the use of the term "insulin resistance" seems justified. H.F. Root*




# Worldwide trends in diabetes prevalence from 1990 to 2022

- In 2022, an estimated 828 million adults had diabetes
- The largest increase was noted in low-income and middle-income countries

Prevalence in 2022




Changes in prevalence  
from 1990 to 2022




# Classification of diabetes


---







# Genes and environment interaction in the development of type 2 diabetes




# BMI alone is not a robust predictor of T2D risk




# Primary beta cell dysfunction vs insulin resistance: who's to blame (first)?



# From "prediabetes" to overt T2D: a continuum of glucose abnormalities and insulin secretory compensation




# From “ominous octet” to “noxious nine”: the evolving picture of the pathogenesis of T2D



# The “incretin effect” is reduced in people with T2D



In people without diabetes, approximately 70% of the insulin secretion following a meal is related to the stimulatory effect of GIP & GLP-1



People without diabetes

People with T2D


## Insulin secretion



# Overview of direct and indirect effects of GIP and GLP-1 in various tissues/organs


*Direct effects:*  
GIP and GLP-1 receptors are expressed in the beta cells, brain, heart and in blood vessels

but NOT in the liver or muscle  
*(indirect effects)*





# Incretins and incretin mimetics induce satiety and reduce the adaptive response to weight loss


- Incretins and incretin mimetics engage the gut-brain axis.
- Due to their long-half life, weekly GLP-1RAs and dual agonists:
  - persistently stimulate the sense of satiety
  - blunt the adaptive response to weight loss



# The abnormal balance between insulin and glucagon is a key factor for the excess hepatic glucose production in DM




# Increased *de novo* lipogenesis is a core defect of T2D and contributes to the accumulation of lipids in the liver



Potential mechanisms for excess FFA 'flux' to the liver:



- De Novo Lipogenesis
- Excess lipolysis
- Dietary intake

# In people with insulin resistance, accumulation of fat in organs (beyond liver) increases risk of T2D, CVD, and CKD




# The increase threshold for glucose renal excretion contributes to hyperglycemia in people with T2D and is restored by SGLT2-inhibitors

(180 L/day) (900 mg/L) = 162 g/day




# Incidence of T1D Varies Between Countries and Over time


Map of age-sex standardized incidence rates (per 100,000) from publications of T1D in children aged under 15 years




Time trends in the incidence of T1D




# Risk genes and environmental factors underlying the insulinitis associated with T1D




# Environmental factors play role in the balance between immune regulation and pathogenesis



# Infiltration of auto-reactive CD8+ lymphocytes is a hallmark of insulinitis in T1D




# Autoimmune process and auto-antibody production precede clinical evidence of T1D




# HLA risk alleles T1D

## Diabetes Risk by HLA DQ and DR Haplotypes


RISK	DRB1	DQA1	DQB1
HIGH	0401,0405,0402 (DR4)	0301	0302
	0301 (DR3)	0501	0201
	0801	0401	0402
MODERATE	0401	0301	0301
	0401	0301	0303
	0403	0301	0302
	0101	0101	0501
	1601	0102	0502
LOW	1101	0501	0301
PROTECTIVE	1501 (DR2)	0102	0602
	0701	0201	0303
	1401	0101	0503



# Development of islet autoantibodies in the offspring of parents with T1D




# Autoimmune process and auto-antibody production precede clinical evidence of T1D




- Offspring of an affected mother is 1% to 4%,
- Offspring of an affected father is 3% to 8%,
- Offspring of both affected parents is as high as 30%;
- Monozygotic twins, the risk of developing T1D the first ten years of diagnosis of the first twin 30%, with a lifetime risk of around 65%
- Vast majority of people diagnosed with T1D have no known family history of T1D

# Impact of age of Diagnosis on progression of C-peptide decline




# In at-risk-children, the number of autoantibodies predicts the risk of progression to T1D



# Screening at-risk people decreases the risk of DKA at diagnosis


Percent with DKA at Diagnosis




# Subgroups of adult-onset diabetes and associations with outcomes

~9,000 people with DM from two independent cohorts were study clustered *at diagnosis* based on:


- GAD antibodies
- BMI
- Age
- HbA1c
- HOMA2-IR and HOMA2-B




11.3%  
6.7%



# Incidence of complications over time by cluster




Time to CKD 3b-V




Diabetes Duration (years)

Time to NPDR



Diabetes Duration (years)

Time to coronary events



Diabetes Duration (years)

## Conclusions

---

- Both Type 1 and Type 2 diabetes results from the interaction of genetic and environmental factors, some of which are modifiable.
- Through rigorous research, multiple pathogenetic factors have been uncovered or are active areas of investigation.
- A better understanding of the communication between tissue and systemic modulators will be essential to guide more precise preventative, diagnostic, and treatment strategies.

**Thank you**

COPYRIGHT